

Empirical proof of first-stick success.
Our peer-reviewed multi-center clinical trials demonstrate unparalleled precision in autonomous venipuncture. By combining near-infrared vein mapping with robotic guidance, the platform consistently achieves first-stick success on difficult venous access patients.
Validated clinical performance
98%
First-stick success rate
35%
Throughput increase
0
Reported adverse events




FDA-cleared safety standards
The VenaBot platform operates under strict autonomous protocols, combining near-infrared vein mapping with real-time tracking to guarantee clinical safety.
FDA Class II Clearance
Sterile Automated Cassette
LIMS Data Integration
FDA Class II clearance ensures the platform adheres to rigorous medical safety and performance standards across hospital networks and commercial diagnostic laboratories.
Our proprietary single-use automated cassette system guarantees zero cross-contamination, maintaining sterile clinical integrity for every patient draw without manual intervention.
Direct integration with laboratory information systems automates sample tracking and documentation, eliminating manual entry errors and streamlining clinical workflows.
Ready to optimize clinical workflows?
Connect directly with our clinical procurement and technical integration teams to review comprehensive safety certifications, detailed laboratory ROI projections, and on-site system deployment requirements.
© 2026 ROPHAI
Forward-Looking Statements: This page contains forward-looking statements regarding our Series A fundraising objectives, planned clinical trials, and regulatory strategies. These statements are based on current expectations and involve inherent risks, delays, and uncertainties regarding medical device development.
Headquarters: Cambridge, MA
info@rophai.com
